292 results about "Pulmonary adenocarcinoma" patented technology

The invention provides a peripheral blood mRNA marker for predicting prognosis of patients with lung adenocarcinoma and a screening method and application thereof and belongs to the technical fields of medical molecular biology and clinical medicine. The screening method includes the steps of 1), comparatively analyzing gene expression profiles of wild-type human lung cancer cell lines and Nrf2 gene knockout human lung cancer cell lines to obtain Nrf2 target genes; 2), analyzing the relationship between Nrf2 target gene expression and the prognosis survival rate of lung adenocarcinoma by the aid of a discovery group database and screening out the genes with the Nrf2 target gene expression Wald statistics greater than 2 in the discovery group database to obtain the periphery blood MRNA marker for predicting prognosis of the patients with the lung adenocarcinoma. The marker obtained with the screening method is applied to predicting prognosis of the patients with clinical lung adenocarcinoma, good flexibility, stability and specificity are achieved, and spreading use can be realized.

The invention provides a micropapilla detection system based on YOLOv5. The micropapilla detection system comprises a lung adenocarcinoma pathological image acquisition module, a detection model training module and a micropapilla detection module; a feature extraction module in the detection model training module adds a layer of feature extraction on the basis of a BottleneckCSP network structure to obtain a shallow feature map, so that the multiple of downsampling of the feature extraction module is reduced by half; the feature fusion module is used for down-sampling the shallow feature map and splicing the shallow feature map with the deep feature map, so that the features of the shallow feature map and the deep feature map are fused, and the small target detection capability of the network is enhanced; and the prediction module replaces the GIoU loss with the CIoU loss, optimizes the prediction frame, improves the regression speed and precision of the prediction frame, and is more suitable for the detection of micronipples.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention provides application of any one or more than two long non-coding RNAs to preparation of a lung adenocarcinoma diagnosing reagent. The LncRNA is LINC00942, LINC00973, AFAP1-AS1 or CLDN10-AS1, wherein the cDNA sequence of the LINC00942 long non-coding RNA is shown as SEQ ID NO.15; the cDNA sequence of the LINC00973 long non-coding RNA is shown as SEQ ID NO.16; the cDNA sequence of the AFAP1-AS1 long non-coding RNA is shown as SEQ ID NO.17; and the cDNA sequence of the CLDN10-AS1 long non-coding RNA is shown as SEQ ID NO.18. The LncRNA can be applied to lung adenocarcinoma diagnosis.

The invention relates to a composition related to lung adenocarcinoma metastasis and application thereof and particularly relates to novel application of the composition composed of one or more of the mir-193a, mir-3942, mir-767, mir-193b and mir-550a-1 and/or matures miRNA for diagnosing the lung adenocarcinoma metastasis. By performing sequencing analysis on the lung adenocarcinoma metastatic group and the non-metastatic group, a reserved drone gene is chosen to perform molecular biology verification. The result shows that the miRNA provided by the invention is closely related to the lung adenocarcinoma metastasis. The composition can be used for clinical diagnosis and preventive detection and has good practical application value.

The invention provides lung adenocarcinoma exosome specific miRNAs, and a target gene and applications thereof. High flux sequencing technology is combined with systematic bioinformatics analysis methods, the specific high-content exosome miRNAs related with lung adenocarcinoma is obtained through screening; the RNA sequences of the lung adenocarcinoma exosome specific miRNAs are represented by SEQ ID No.1-3. It is found that the common target gene of the miRNAs is FOXN3. The target gene is capable of inhibiting fibroblast migration capability, reduction of the expression amount of the targetgene is capable of promoting entering of fibroblast into tumor tissues, and promoting tumor growth. The lung adenocarcinoma exosome specific miRNAs and the target gene thereof can be taken as lung adenocarcinoma diagnosis markers and can be used for preparation of diagnostic kits. An inhibitor of the miRNAs or an expression promoter of the target gene can be used for preparing medicines used for treating lung adenocarcinoma, or medication guidance in treatment of lung adenocarcinoma; and the clinical application value is relatively high, and the application prospect is promising.

The invention discloses a mark used for prediction of prognosis of a lung adenocarcinoma. The mark is composed of OPN3, GALNT2, FAM83A AND KYUN, and a mathematical model for prediction of prognosis ofthe lung adenocarcinoma is established based on the four indexes of OPN3, GALNT2, FAM83A AND KYUN, wherein the expression formula of the mathematical model is P=0.0004A+0.0042B+0.0055C+0.0077D, in the formula, P is a risk coefficient, A is the expression quantity of OPN3, B is the expression quantity of GALANT2, C is the expression quantity of FAM83A, and D is the expression quantity of KYNU. When P is higher than 0.216, it is defined to have a high risk, and otherwise it is defined to have a low risk. The prediction for AUC of the prognosis of the lung adenocarcinoma reaches 0.71 through themodel, when cut-off is 0.216, the sensitiveness of predicting a three-year overall life cycle of a patient with the lung adenocarcinoma is 53.3% through the mode, specificity is 82.9%, the average overall life cycle of patient groups with high risks of the lung adenocarcinoma is about 46 months, and the average overall life cycle of patient groups with low risks is about 94 months.

The invention discloses an auxiliary identification system and method for lung adenocarcinoma subtypes, and relates to a neural network. The system comprises an acquisition module for acquiring a digital pathological image and labeling to obtain a labeled image; wherein the features include lesion areas and real pathological image features; the processing module is used for processing the annotated image to obtain a processed image and storing the processed image into a database; the classification module divides the processed images into a training set, a verification set and a test set; thetraining module is used for training the training set to obtain an auxiliary identification model of the lung adenocarcinoma subtype; the verification module is used for inputting the verification setinto the auxiliary identification model for optimization to obtain an optimization model; the test module is used for inputting the test set into the optimization model to obtain a result and obtaintest accuracy; the comparison module is used for comparing the test accuracy with a test threshold value and retraining when the test accuracy is smaller than the test threshold value; and if not, storing the auxiliary identification optimization model. The kit has the beneficial effect of assisting a clinician in identifying the lung adenocarcinoma subtype.

The invention discloses a human lung adenocarcinoma cell line and an application thereof. The human lung adenocarcinoma cell line is preserved at China Center for Type Culture Collection (CCTCC) on May 23th, 2014, in Wuhan University 430072, China. The name of a culture is human lung adenocarcinoma cell ZRLC-1; and a preservation number is CCTCC NO: C2014103. The human lung adenocarcinoma cell ZRLC-1 can be used as an experimental material in lung adenocarcinoma basic and clinical research, and can be used for establishing an animal model for occurrence, development and metastasis of lung cancers. The human lung adenocarcinoma cell line has stable characters, can be sub-cultured for a plurality of times stably, and can highly express epithelial markers such as EpCAM and E-cadherin. Flow cytometric analysis shows that EpCAM positive cells reach over 99.70%; and novel experiment material closer to the biological characteristics of clinical tumors are provided for the research of the lung cancers.

Provided are phenanthroindolizidine alkaloid derivates and salt thereof as well as preparation, a plant-virus resisting activity, and an anti-cancer activity of phenanthroindolizidine alkaloid derivates and salt thereof. The derivates and the salt thereof have a good plant-virus resisting activity, which is capable of well restraining a tobacco mosaic virus (TMV), and meanwhile, have a good anti-cancer activity, which is capable of well restraining the human lung adenocarcinoma A-549 and the human leukemia HL-60.

The invention discloses application of an LOC101928926 gene which is used for preparing a product for diagnosing pulmonary adenocarcinoma. The invention further discloses application of the LOC101928926 gene in preparing or screening medicine for treating pulmonary adenocarcinoma. The LOC101928926 gene related to occurrence and development of pulmonary adenocarcinoma can serve as a biological marker of pulmonary adenocarcinoma to help a doctor make individualized treatment schemes, and meanwhile the pulmonary adenocarcinoma serves as a medicine target for treating tumors.

The invention belongs to the filed of microorganism animal cell lines and provides a Chinese lung adenocarcinoma cell line with high metastases potentiality of bone, lever and adrenal gland. According to the invention, hydrothorax of an adenocarcinoma first-diagnosis patient is used as primary culture of cells; the human adenocarcinoma cell has the preservation number of CGMCC No.3137 and classified name as human lung adenocarcinoma cell line CPA-Yang3, can grow adhered to the wall and has the tumorigenesis rate up to 100 percent; the human lung adenocarcinoma cell can grow quickly and metabolize vigorously; the expression levels of cancer genes EMS1, VEGF-C, IL-6, IL-8, SVIL and AR gene are higher than the expression level of SPC-A-1 cell; and the lung adenocarcinoma cancel cell has the biological characteristics of mainly transferring the bone and having high transfer potential of the lever and the adrenal gland, high growth speed of bone transfer cells and complete cell morphology. The invention can be used for providing reference data to early diagnosis for transferring the human lung adenocarcinoma bone, further establishing the relevant gene chip technology and assessing and exploring the curative effects of various medicaments and the like by comprehensively applying the gene chip, quantifying PCR (Polymerase Chain Reaction), western blot in real time and other technologies.

The invention belongs to the technical field of biology, discloses a gene group capable of evaluating primary lung adenocarcinoma molecular typing and survival risk, and discloses application of reagents for detecting gene expression levels of the gene group in preparing in-vitro diagnostic products for evaluating primary lung adenocarcinoma molecular typing and survival risk. The in-vitro diagnostic products comprise a Next Generation Sequencing (NGS) detection kit, a fluorescent quantitative PCR detection kit, a gene chip and a protein array. The invention further discloses a method for evaluating primary lung adenocarcinoma molecular typing and survival risk by utilizing the detection kits. The method disclosed by the invention has high accuracy on evaluation of primary lung adenocarcinoma subtype typing and survival risk.

An application of isorhamnetin and its derivatives in preparing medicines for treating cervical cancer, liver cancer, squamous cell carcinoma of tongue, lung adenocar cinoma, etc is disclosed. Said isorhamnetin and its derivatives may be isorhammetin aglycone and isohamnoside. Its advantages are high curative effect, low toxic by-effect.

The invention discloses a prognosis evaluation system for patients with early-stage LUAD and application thereof. According to the invention, disease-free survival data of 632 patients with early-stage LUAD in three independent queues are integrated, and an individual IBRS model for patients with early-stage LUAD is established and verified. The three independent queues include TCGA, GSE31210 and68 cases of frozen tissues. The IBRS model is composed of the following nine genes: DYNC1I2, THOC1, ADAM10, SERPINB6, CCL20, WNT2B, SLC11A1, MAPT and PSEN1. The establishment of the IBRS model for patients with early-stage LUAD is not only beneficial for understanding of the complex interaction mechanism between immune molecules, but also brings great help to the recurrence prediction of the patients with early-stage LUAD and the optimization of a treatment scheme.